-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Life Sciences Solutions
-
Healthcare Solutions
-
Medical Device and Diagnostic
-
U.S. Government
Life Sciences Solutions
Bringing together unparalleled healthcare data, advanced analytics, innovative technologies, and healthcare expertise to create intelligent connections that speed the development and commercialization of innovative medicines to improve patient lives.
Learn MoreLife Sciences Solutions
Healthcare Solutions
Accelerate digital innovation to enable smarter decisions that reduce cost, modernize patient and consumer engagement, and improve health outcomes.
Learn MoreHealthcare Solutions
Medical Device and Diagnostic Solutions
Your world is unique – and quite different from pharma. In the U.S., decision-making has shifted from individual physicians to integrated networks--GPOs, IDNs and payers. These groups have heightened the focus on proving your solution’s value, demanding outcomes analyses and putting pressure on pricing.
Learn MoreMedical Device and Diagnostic Solutions
U.S. Government Solutions
For government agencies and organizations at every level—from federal or national to regional and local—Big Data can have a huge impact on public health.
Learn MoreU.S. Government Solutions
U.S. PROGRESS POINT
A curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREU.S. BLOGS
Get the latest insights on our life sciences, healthcare, and medical technology solutions in the United States. Follow our blog today!
LEARN MORE
Blog
The Cures Act: Is There Value in Going Beyond Minimum Compliance?
Jul 21, 2020
Following numerous conversations among health care organization leaders, a vast spectrum of implementation approaches has emerged with respect to preparation for interoperability and the 21st Century Cures Act. Healthcare organizations are also in various stages of implementation, from those just getting started to those who are well underway in meeting the federal mandate. Perhaps the most interesting discussions center on what, at a minimum, is needed on January 1, 2021 when the Act goes into effect, and what can wait for later stages of the program.
With so much uncertainty in the healthcare delivery space, given the impact of COVID-19, the state of the U.S. economy and consumer confidence, and the undefined timeframe for resuming in-person delivered healthcare, many implementing the Cures Act are favoring minimum compliance. Specifically, healthcare payers will support public Application Programming Interfaces (APIs) to provide drug formulary information and provider directories. Additionally, they will provide an API for members to access up to five years of claim and encounter information, as well as the clinical data the organization manages.
Healthcare providers must also support patient access to their health data through third-party APIs. They will all support these APIs and share member-requested data at no cost to the consumer. No information blockers here! However, the consensus seems to favor that only a small volume of their consumers will embrace the new data availability initially and use this as their main argument for delaying a value-add solution, which is anything beyond minimum compliance. They may be right.
However, what if the providers are wrong, and their current and former consumers have been waiting for this opportunity to access their personal healthcare information? Imagine seeing five years of claim, encounter, and clinical data, filled with unfamiliar code sets and clinical shorthand.
The data will be presented in the correct format but left to the interpretation of the third-party application the member selected to access the data. This may be the case in some scenarios, but what if there were tools available and promoted by the healthcare organization, and powered by data analytics and Artificial Intelligence (AI) engines that could help a consumer find better answers to their medical questions than a search engine? Imagine a presentation layer that is as informative as it is intuitive, and encourages a consumer to examine their overall picture of health in a contextual format that presents both a clinical and financial view of healthcare possibilities.
At a minimum, the Cures Act promotes the sharing of healthcare data by establishing the patient as the data owner. A healthcare organization can offer a deeper perspective by presenting data in context, helping the consumer interpret their healthcare data, and establishing the beginning of a direct-to-consumer value-added solution. This is just one of many ways a healthcare organization can go beyond minimum compliance and embrace the true spirit of interoperability and the intent of the Cures Act.
For some healthcare organizations, the time may not be right to deploy a value-added Cures Act solution. What is important is that any solution deployed for the January 1, 2021 timeline allow for a future value-add solution without requiring rework. Borrowing a line from the movie, Field of Dreams, “If you build it, he (they) will come.” By making an investment in interoperability beyond minimum compliance, member engagement will increase, which can lead to better health outcomes and an improved consumer experience. This can differentiate your organization and establish it as a market leader.
The good news is that there is still time to develop an action plan to implement the required Cures Act changes. IQVIA offers a range of consulting services to assist healthcare organizations with assessing, planning, and implementing the changes required to comply with the Cures Act.
If you are not familiar with the Cures Act and interoperability, or would like more detail and an overview, download our white paper Cures Act: Getting Ready for the Implementation of TEFCA and Healthcare Interoperability Standards.
Cures Act: Getting Ready for the Implementation of TEFCA and Healthcare Interoperability Standards
In this white paper, IQVIA experts walk through the 21st Century Cures Act and the set of final rules mandating regulatory compliance for healthcare information exchange.